Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12176 - 12200 of 14624 in total
Investigational
Investigational
Investigational
Investigational
Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).
Investigational
Matched Description: … a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and
Investigational
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
Investigational
LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Investigational
APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
Investigational
Nanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra).
Investigational
Matched Description: … Nanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity …
CPGJ602 is a recombinant anti-EGFR human-mouse chimeric monoclonal antibody.
Investigational
Investigational
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
Investigational
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
Matched Description: … encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and
Investigational
Investigational
Investigational
RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (Treg) cells. RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.).
Investigational
Matched Description: … RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability …
IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Description: … trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and
Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction. It is being investigated for cancers.
Investigational
Matched Description: … Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and
Displaying drugs 12176 - 12200 of 14624 in total